Aurobindo Pharma Past Earnings Performance
Past criteria checks 4/6
Aurobindo Pharma's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 5.1% per year. Aurobindo Pharma's return on equity is 11.6%, and it has net margins of 11.8%.
Key information
-5.3%
Earnings growth rate
-5.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.1% |
| Return on equity | 11.6% |
| Net Margin | 11.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Revenue & Expenses Breakdown
How Aurobindo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 302,950 | 35,816 | 43,179 | 0 |
| 30 Jun 24 | 297,184 | 35,214 | 41,633 | 0 |
| 31 Mar 24 | 290,019 | 31,730 | 40,434 | 0 |
| 31 Dec 23 | 278,947 | 27,705 | 38,823 | 0 |
| 30 Sep 23 | 269,500 | 23,254 | 38,143 | 0 |
| 30 Jun 23 | 254,700 | 19,777 | 37,278 | 0 |
| 31 Mar 23 | 248,554 | 19,275 | 36,560 | 0 |
| 31 Dec 22 | 241,918 | 19,977 | 36,478 | 0 |
| 30 Sep 22 | 237,869 | 21,112 | 35,950 | 0 |
| 30 Jun 22 | 239,894 | 23,987 | 35,854 | 0 |
| 31 Mar 22 | 234,555 | 26,482 | 35,751 | 0 |
| 31 Dec 21 | 236,476 | 28,676 | 35,746 | 0 |
| 30 Sep 21 | 240,103 | 52,109 | 35,865 | 0 |
| 30 Jun 21 | 245,518 | 53,217 | 36,395 | 0 |
| 31 Mar 21 | 247,746 | 53,348 | 36,576 | 0 |
| 31 Dec 20 | 249,316 | 53,831 | 36,591 | 0 |
| 30 Sep 20 | 244,617 | 31,421 | 35,761 | 0 |
| 30 Jun 20 | 235,787 | 29,757 | 34,414 | 0 |
| 31 Mar 20 | 230,985 | 28,451 | 33,333 | 0 |
| 31 Dec 19 | 222,323 | 25,666 | 32,224 | 0 |
| 30 Sep 19 | 216,070 | 25,733 | 30,744 | 0 |
| 30 Jun 19 | 207,579 | 25,449 | 29,226 | 0 |
| 31 Mar 19 | 195,636 | 23,647 | 27,389 | 0 |
| 31 Dec 18 | 183,834 | 23,078 | 25,632 | 0 |
| 30 Sep 18 | 174,246 | 21,906 | 24,541 | 0 |
| 30 Jun 18 | 171,091 | 23,603 | 23,473 | 0 |
| 31 Mar 18 | 164,630 | 24,232 | 22,414 | 0 |
| 31 Dec 17 | 159,381 | 24,271 | 20,903 | 0 |
| 30 Sep 17 | 154,903 | 24,107 | 19,953 | 0 |
| 30 Jun 17 | 148,279 | 22,352 | 19,032 | 0 |
| 31 Mar 17 | 149,334 | 23,017 | 18,451 | 0 |
| 31 Dec 16 | 151,565 | 22,809 | 17,799 | 0 |
| 30 Sep 16 | 147,559 | 22,466 | 17,359 | 0 |
| 30 Jun 16 | 143,446 | 20,945 | 16,823 | 0 |
| 31 Mar 16 | 138,162 | 20,251 | 16,019 | 0 |
| 31 Dec 15 | 133,249 | 18,230 | 28,438 | 894 |
| 30 Sep 15 | 129,956 | 16,724 | 27,775 | 894 |
| 30 Jun 15 | 125,433 | 15,928 | 26,938 | 894 |
| 31 Mar 15 | 121,340 | 15,758 | 13,548 | 0 |
| 31 Dec 14 | 112,825 | 16,738 | 17,756 | 624 |
| 30 Sep 14 | 102,756 | 17,069 | 16,210 | 624 |
| 30 Jun 14 | 93,109 | 15,697 | 14,800 | 624 |
| 31 Mar 14 | 81,002 | 11,729 | 13,273 | 624 |
| 31 Dec 13 | 73,736 | 7,797 | 12,261 | 423 |
Quality Earnings: AUROPHARMA has high quality earnings.
Growing Profit Margin: AUROPHARMA's current net profit margins (11.8%) are higher than last year (8.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AUROPHARMA's earnings have declined by 5.3% per year over the past 5 years.
Accelerating Growth: AUROPHARMA's earnings growth over the past year (54%) exceeds its 5-year average (-5.3% per year).
Earnings vs Industry: AUROPHARMA earnings growth over the past year (54%) exceeded the Pharmaceuticals industry 20.4%.
Return on Equity
High ROE: AUROPHARMA's Return on Equity (11.6%) is considered low.